Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 17;4(1):e000212.
doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Kevin R Flaherty  1 , Kevin K Brown  2 , Athol U Wells  3 , Emmanuelle Clerisme-Beaty  4 , Harold R Collard  5 , Vincent Cottin  6 , Anand Devaraj  7 , Yoshikazu Inoue  8 , Florence Le Maulf  9 , Luca Richeldi  10 , Hendrik Schmidt  11 , Simon Walsh  12 , William Mezzanotte  4 , Rozsa Schlenker-Herceg  13
Affiliations

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Kevin R Flaherty et al. BMJ Open Respir Res. .

Abstract

600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on HRCT. The primary endpoint is the annual rate of decline in forced vital capacity over 52 weeks. The main secondary endpoints are the absolute change from baseline in King's Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks.

Ethics and dissemination: The trial is conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (GCP) and Japanese GCP regulations.

Trial registration number: NCT02999178.

Keywords: interstitial fibrosis; rare lung diseases.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KRF reports grants and personal fees from Genentech, grants from Afferent, and personal fees from Boehringer Ingelheim, Veracyte, Roche, Biogen, Aeolus and Pharmakea. KKB reports grants from NHLBI, grants and personal fees from Actelion, Amgen, Gilead, and personal fees from Almiral, Altitude Pharma, Astra Zeneca, Byer, Biogen/Stromedix, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Fibrogen, Galecto, GlaxoSmithKline, MedImmune, Novartis, Pfizer, Promedior, Roche/Genentech, Sanofi/Genzyme, Veracyte, Aeolus and ProMetic. AUW reports lecturing and consultancy fees from Boehringer Ingelheim, Roche, InterMune, Actelion and Bayer. HRC reports personal fees from MedImmune, Bayer, Biogen, Boehringer Ingelheim, Xfibra, Genoa, Gilead, GlaxoSmithKline, Mesoblast, Moerae Matrix, PharmAkea, Promedior, Prometic, Pulmatrix, Pulmonary Fibrosis Foundation (senior medical advisor), Unity, Aeolus, aTyr Pharmaceuticals, Pfizer, UCB Celltech, GBT, Veracyte, Patara, Samumed, Alkermes, Five Prime and Takeda. VC reports personal fees from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, Intermune, MSD, Novartis, Pfizer, Roche and Sanofi, grants from Actelion, Boehringer Ingelheim, GSK, Pfizer and Roche, and personal fees from Boehringer Ingelheim. YI reports lecture and advisory fees from Boehringer Ingelheim, Shionogi & Co., Ltd., Takeda, Nobel Pharma, Novartis, Serendex, Bayer, Chugai and Daiichi Sankyo. LR reports grants and personal fees from InterMune, and personal fees from MedImmune, Biogen, SanofiAventis, Roche, Takeda, ImmuneWorks, Shionogi, Boehringer Ingelheim and Pliant Therapeutics. ECB, HS, WM and RSH are full-time employees of Boehringer Ingelheim. FLM was a full-time employee of Boehringer Ingelheim at the time of manuscript development. SW and AD report no competing interests.

Figures

Figure 1
Figure 1
Trial design. Study design schematic of the PF-ILD trial followed by a separate open-label trial (optional): part A (visits 1 through 9 over 52 weeks) and part B (visit 10 through EOT visit over variable period for each patient). EOT, end of treatment; PF-ILD, progressive fibrosing interstitial lung disease; R, randomisation (1:1 ratio for nintedanib:placebo).
See this image and copyright information in PMC

References

    1. Valeyre D, Duchemann B, Nunes H, et al. ; Interstitial lung diseases In: Annesi-Maesano I, Lundbäck B, Viegi G, eds Respiratory epidemiology, 2014:79–87.
    1. Walsh SL, Sverzellati N, Devaraj A, et al. . Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014;69:216–22. doi:10.1136/thoraxjnl-2013-203843 - DOI - PubMed
    1. Travis WD, Costabel U, Hansell DM, et al. . An official American Thoracic Society/European respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48. doi:10.1164/rccm.201308-1483ST - DOI - PMC - PubMed
    1. Akira M, Inoue Y, Arai T, et al. . Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax 2011;66:61–5. doi:10.1136/thx.2010.140574 - DOI - PubMed
    1. Kim EJ, Elicker BM, Maldonado F, et al. . Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322–8. doi:10.1183/09031936.00092309 - DOI - PubMed

Associated data